12.91

0.16% 0.02

After Hours: 12.88 -0.03 -0.23%

Arcturus Therapeutics Holdings Inc (ARCT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arcturus Therapeutics Holdings Inc stock is traded at $12.91, with a volume of 279.42K. It is up +0.16% in the last 24 hours and up +1.10% over the past month. Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

Previous Close:

$12.89

Open:

$12.87

24h Volume:

279.42K

Relative Volume:

0.66

Market Cap:

$298.32M

Revenue:

$157.75M

Net Income/Loss:

$-29.73M

P/E Ratio:

-11.13

EPS:

-1.16

Net Cash Flow:

$-21.00M

1W Performance:

+22.60%

1M Performance:

+1.10%

6M Performance:

-31.87%

1Y Performance:

-50.67%

1-Day Range:

$12.29

$12.97

1-Week Range:

$10.21

$13.66

52-Week Range:

$8.04

$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name

Arcturus Therapeutics Holdings Inc

Sector

Healthcare (1168)

Industry

Biotechnology (677)

Phone

(858) 900-2660

Address

10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Employee

176

Twitter

@ArcturusRx

Next Earnings Date

2024-11-07

Latest SEC Filings

ARCT's Discussions on Twitter

Compare ARCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARCT Arcturus Therapeutics Holdings Inc	12.91	298.32M	157.75M	-29.73M	-21.00M	-1.16
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-25	Initiated	BTIG Research	Buy
Aug-12-24	Initiated	Leerink Partners	Outperform
Dec-13-23	Initiated	Canaccord Genuity	Buy
Jul-24-23	Initiated	William Blair	Outperform
May-11-23	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-14-22	Resumed	Wells Fargo	Overweight
Nov-10-22	Downgrade	Robert W. Baird	Neutral → Underperform
Nov-03-22	Upgrade	Citigroup	Neutral → Buy
Nov-02-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-10-22	Downgrade	Raymond James	Mkt Perform → Underperform
Jul-19-22	Resumed	Cantor Fitzgerald	Overweight
May-11-22	Upgrade	Robert W. Baird	Underperform → Neutral
Apr-21-22	Downgrade	Citigroup	Buy → Neutral
Jan-31-22	Upgrade	Raymond James	Underperform → Mkt Perform
Aug-12-21	Downgrade	Raymond James	Mkt Perform → Underperform
Aug-11-21	Downgrade	Goldman	Neutral → Sell
Aug-10-21	Downgrade	Robert W. Baird	Neutral → Underperform
Jul-02-21	Initiated	Cantor Fitzgerald	Overweight
Jun-25-21	Resumed	Goldman	Neutral
Jun-21-21	Downgrade	Barclays	Equal Weight → Underweight
Jun-04-21	Resumed	Robert W. Baird	Neutral
Feb-17-21	Downgrade	B. Riley Securities	Neutral → Sell
Jan-19-21	Downgrade	B. Riley Securities	Buy → Neutral
Jan-15-21	Downgrade	B. Riley Securities	Buy → Neutral
Jan-07-21	Initiated	Wells Fargo	Overweight
Dec-29-20	Downgrade	Barclays	Overweight → Equal Weight
Dec-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-29-20	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-29-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-23-20	Downgrade	ROTH Capital	Buy → Sell
Dec-08-20	Reiterated	B. Riley Securities	Buy
Dec-07-20	Reiterated	B. Riley Securities	Buy
Oct-26-20	Initiated	Barclays	Overweight
Oct-06-20	Initiated	Citigroup	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-30-20	Resumed	ROTH Capital	Buy
Jul-16-20	Initiated	Raymond James	Outperform
Jul-13-20	Initiated	B. Riley FBR	Buy
Jun-09-20	Downgrade	WBB Securities	Buy → Hold
Feb-11-20	Initiated	Robert W. Baird	Outperform
Feb-07-20	Initiated	Guggenheim	Buy
Feb-06-20	Initiated	Guggenheim	Buy
Apr-05-19	Initiated	H.C. Wainwright	Buy
Sep-20-18	Upgrade	WBB Securities	Buy → Strong Buy
Jan-22-18	Initiated	Chardan Capital Markets	Buy

View All

Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News

Apr 24, 2025

Geode Capital Management LLC Has $9.42 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 24, 2025

Apr 23, 2025

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - ADVFN

Apr 23, 2025

Apr 22, 2025

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 - Business Wire

Apr 22, 2025

Long Term Trading Analysis for (ARCT) - news.stocktradersdaily.com

Apr 22, 2025

Apr 21, 2025

JPMorgan Chase & Co. Has $4.01 Million Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 21, 2025

Apr 19, 2025

Q1 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World

Apr 19, 2025

Apr 18, 2025

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine (PR Newswire) - Aktiellt

Apr 18, 2025

Apr 15, 2025

Vanguard Group Inc. Grows Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 15, 2025

Apr 13, 2025

Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN

Apr 13, 2025

Apr 12, 2025

KLP Kapitalforvaltning AS Acquires New Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 12, 2025

HC Wainwright Reiterates Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World

Apr 12, 2025

Apr 11, 2025

High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st

Apr 11, 2025

Arcturus Therapeutics (ARCT) Gains FDA Fast Track for Influenza Vaccine - GuruFocus

Apr 11, 2025

Arcturus Therapeutics (ARCT) Receives Fast Track Status for Infl - GuruFocus

Apr 11, 2025

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation f - GuruFocus

Apr 11, 2025

Guggenheim Lowers Price Target for Arcturus Therapeutics (ARCT) Amid Risk Adjustments | ARCT Stock News - GuruFocus

Apr 11, 2025

Apr 10, 2025

Arcturus wins FDA fast track status for influenza vaccine - MSN

Apr 10, 2025

Arcturus wins FDA fast track status for flu shot (ARCT:NASDAQ) - Seeking Alpha

Apr 10, 2025

Arcturus Therapeutics Says FDA Granted Fast Track Designation to Potential H5N1 Vaccine - marketscreener.com

Apr 10, 2025

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 - Business Wire

Apr 10, 2025

Breakthrough: FDA Fast-Tracks Revolutionary mRNA Vaccine Against Deadly H5N1 Pandemic Flu - Stock Titan

Apr 10, 2025

Apr 09, 2025

Commonwealth Equity Services LLC Reduces Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 09, 2025

Apr 07, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $59.20 Consensus Price Target from Brokerages - Defense World

Apr 07, 2025

Apr 06, 2025

(ARCT) Investment Report - news.stocktradersdaily.com

Apr 06, 2025

Mar 26, 2025

(ARCT) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Mar 26, 2025

Mar 24, 2025

Bank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Mar 24, 2025

Mar 20, 2025

Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey

Mar 20, 2025

Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st

Mar 20, 2025

Mar 18, 2025

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN

Mar 18, 2025

Mar 17, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $61.40 Average PT from Analysts - Defense World

Mar 13, 2025

Mar 12, 2025

Arcturus Therapeutics at Leerink’s Conference: mRNA Innovations and Strategic Plans - Investing.com UK

Mar 12, 2025

Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism - markets.businessinsider.com

Mar 12, 2025

Mar 11, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group - Defense World

Mar 11, 2025

Mar 09, 2025

Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - Simply Wall St

Mar 09, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo

Mar 09, 2025

HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $60.00 - Defense World

Mar 09, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald - Defense World

Mar 09, 2025

Mar 08, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025

Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 By Investing.com - Investing.com Australia

Mar 07, 2025

Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock - Benzinga

Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 - Investing.com India

Mar 07, 2025

Earnings call transcript: Arcturus Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com South Africa

Mar 07, 2025

Arcturus Therapeutics Reports Q4 2024 Earnings: EPS of ($1.11) M - GuruFocus.com

Mar 07, 2025